CCR6 As a Potential Target for Therapeutic Antibodies for the Treatment of Inflammatory Diseases

Overview

Journal Antibodies (Basel)

Date 2023 Apr 24

PMID 37092451

Authors

Sara Gomez-Melero

Javier Caballero-Villarraso

Affiliations

Soon will be listed here.

Abstract

The CC chemokine receptor 6 (CCR6) is a G protein-coupled receptor (GPCR) involved in a wide range of biological processes. When CCR6 binds to its sole ligand CCL20, a signaling network is produced. This pathway is implicated in mechanisms related to many diseases, such as cancer, psoriasis, multiple sclerosis, HIV infection or rheumatoid arthritis. The CCR6/CCL20 axis plays a fundamental role in immune homeostasis and activation. Th17 cells express the CCR6 receptor and inflammatory cytokines, including IL-17, IL-21 and IL-22, which are involved in the spread of inflammatory response. The CCL20/CCR6 mechanism plays a crucial role in the recruitment of these pro-inflammatory cells to local tissues. To date, there are no drugs against CCR6 approved, and the development of small molecules against CCR6 is complicated due to the difficulty in screenings. This review highlights the potential as a therapeutic target of the CCR6 receptor in numerous diseases and the importance of the development of antibodies against CCR6 that could be a promising alternative to small molecules in the treatment of CCR6/CCL20 axis-related pathologies.

Citing Articles

Impact of obesity on the CCR6-CCL20 axis in epidermal γδ T cells and IL-17A production in murine wound healing and psoriasis.

Lawler W, Castellanos T, Engel E, Alvizo C, Kasler A, Bshara-Corson S J Immunol. 2025; 214(1):153-166.

PMID: 40073267 PMC: 11844138. DOI: 10.1093/jimmun/vkae011.

Chemokines Signature and T Cell Dynamics in Leishmaniasis: Molecular insight and therapeutic application.

Upadhyay S, Kumar S, Singh V, Tiwari R, Kumar A, Sundar S Expert Rev Mol Med. 2024; 1-55.

PMID: 39587036 PMC: 11707835. DOI: 10.1017/erm.2024.36.

Many Faces of Regulatory T Cells: Heterogeneity or Plasticity?.

Blinova V, Zhdanov D Cells. 2024; 13(11.

PMID: 38891091 PMC: 11171907. DOI: 10.3390/cells13110959.

Targeting immune cell recruitment in atherosclerosis.

Doring Y, van der Vorst E, Weber C Nat Rev Cardiol. 2024; 21(11):824-840.

PMID: 38664575 DOI: 10.1038/s41569-024-01023-z.

Impact of Obesity on the CCR6-CCL20 Axis in Epidermal γδ T Cells and IL-17A Production in Murine Wound Healing and Psoriasis.

Lawler W, Castellanos T, Engel E, Alvizo C, Kasler A, Bshara-Corson S bioRxiv. 2024; .

PMID: 38645150 PMC: 11030331. DOI: 10.1101/2024.04.09.588780.

References

Lee A, Phan T, Hulett M, Korner H . The relationship between CCR6 and its binding partners: does the CCR6-CCL20 axis have to be extended?. Cytokine. 2015; 72(1):97-101. DOI: 10.1016/j.cyto.2014.11.029. View

Kumari P, Ghosh E, Shukla A . Emerging Approaches to GPCR Ligand Screening for Drug Discovery. Trends Mol Med. 2015; 21(11):687-701. DOI: 10.1016/j.molmed.2015.09.002. View

Wang C, Kang S, Lee J, Sun Z, Kim C . The roles of CCR6 in migration of Th17 cells and regulation of effector T-cell balance in the gut. Mucosal Immunol. 2009; 2(2):173-83. PMC: 2709747. DOI: 10.1038/mi.2008.84. View

Campbell J, Ebsworth K, Ertl L, McMahon J, Newland D, Wang Y . IL-17-Secreting γδ T Cells Are Completely Dependent upon CCR6 for Homing to Inflamed Skin. J Immunol. 2017; 199(9):3129-3136. DOI: 10.4049/jimmunol.1700826. View

Kim S, Fristrup P, Abrol R, Goddard 3rd W . Structure-based prediction of subtype selectivity of histamine H3 receptor selective antagonists in clinical trials. J Chem Inf Model. 2011; 51(12):3262-74. PMC: 3246544. DOI: 10.1021/ci200435b. View

Shimizu Y, Murata H, Kashii Y, Hirano K, Kunitani H, Higuchi K . CC-chemokine receptor 6 and its ligand macrophage inflammatory protein 3alpha might be involved in the amplification of local necroinflammatory response in the liver. Hepatology. 2001; 34(2):311-9. DOI: 10.1053/jhep.2001.26631. View

Renaude E, Kroemer M, Loyon R, Binda D, Borg C, Guittaut M . The Fate of Th17 Cells is Shaped by Epigenetic Modifications and Remodeled by the Tumor Microenvironment. Int J Mol Sci. 2020; 21(5). PMC: 7084267. DOI: 10.3390/ijms21051673. View

Zhang X, Hu Z, Meng A, Duan G, Zhao Q, Yang J . Role of CCL20/CCR6 and the ERK signaling pathway in lung adenocarcinoma. Oncol Lett. 2017; 14(6):8183-8189. PMC: 5727607. DOI: 10.3892/ol.2017.7253. View

Lee G . The Balance of Th17 versus Treg Cells in Autoimmunity. Int J Mol Sci. 2018; 19(3). PMC: 5877591. DOI: 10.3390/ijms19030730. View

10.

Millar R, Newton C . The year in G protein-coupled receptor research. Mol Endocrinol. 2009; 24(1):261-74. PMC: 5428143. DOI: 10.1210/me.2009-0473. View

11.

Baba M, Imai T, Nishimura M, Kakizaki M, Takagi S, Hieshima K . Identification of CCR6, the specific receptor for a novel lymphocyte-directed CC chemokine LARC. J Biol Chem. 1997; 272(23):14893-8. DOI: 10.1074/jbc.272.23.14893. View

12.

Demedts I, Bracke K, Van Pottelberge G, Testelmans D, Verleden G, Vermassen F . Accumulation of dendritic cells and increased CCL20 levels in the airways of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007; 175(10):998-1005. DOI: 10.1164/rccm.200608-1113OC. View

13.

Yang D, Zhou Q, Labroska V, Qin S, Darbalaei S, Wu Y . G protein-coupled receptors: structure- and function-based drug discovery. Signal Transduct Target Ther. 2021; 6(1):7. PMC: 7790836. DOI: 10.1038/s41392-020-00435-w. View

14.

Smith J, Rajagopal S . The β-Arrestins: Multifunctional Regulators of G Protein-coupled Receptors. J Biol Chem. 2016; 291(17):8969-77. PMC: 4861465. DOI: 10.1074/jbc.R115.713313. View

15.

Kadomoto S, Izumi K, Mizokami A . The CCL20-CCR6 Axis in Cancer Progression. Int J Mol Sci. 2020; 21(15). PMC: 7432448. DOI: 10.3390/ijms21155186. View

16.

Hedrick M, Lonsdorf A, Hwang S, Farber J . CCR6 as a possible therapeutic target in psoriasis. Expert Opin Ther Targets. 2010; 14(9):911-22. PMC: 3700805. DOI: 10.1517/14728222.2010.504716. View

17.

Mackay C . Moving targets: cell migration inhibitors as new anti-inflammatory therapies. Nat Immunol. 2008; 9(9):988-98. DOI: 10.1038/ni.f.210. View

18.

Ito T, Carson 4th W, Cavassani K, Connett J, Kunkel S . CCR6 as a mediator of immunity in the lung and gut. Exp Cell Res. 2011; 317(5):613-9. PMC: 3063449. DOI: 10.1016/j.yexcr.2010.12.018. View

19.

Korona B, Korona D, Zhao W, Wotherspoon A, Du M . CCR6 activation links innate immune responses to mucosa-associated lymphoid tissue lymphoma development. Haematologica. 2022; 107(6):1384-1396. PMC: 9152962. DOI: 10.3324/haematol.2021.280067. View

20.

Saris A, Reijnders T, Reijm M, Hollander J, de Buck K, Schuurman A . Enrichment of CCR6 CD8 T cells and CCL20 in the lungs of mechanically ventilated patients with COVID-19. Eur J Immunol. 2021; 51(6):1535-1538. PMC: 8250259. DOI: 10.1002/eji.202049046. View